AVX 13616

CAT: 0804-HY-16672Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-16672Size:1 Each
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
AVX 13616 shows the potent in vivo antibacterial activity of Avexa’s lead antibacterial candidate; particularly against drug-resistant Staphylococcus pathogens. IC50 value: 2-4 ug/ml (MICs) Target: antibacterial agent AVX13616 was as active as mupirocin in a nasal decolonization model but required only a single application. The compounds are being developed for topical indications and/or wound infection/catheter-related infections. AVX13616 and other compounds showed broad spectrum antibacterial activity against a range of isolates with MICs of 2-4 micrograms per millilitre against S. aureus, coagulase negative staphylococci, enterococci, MRSA, VISA and VRSA. A single application of 5% (w/w) AVX13616 (approximately equimolar to 2% mupirocin) was as effective as 2% mupirocin administered twice a day for five days in nasal decolonisation of MRSA in mice.
CAS Number
[900814-48-4]
UNSPSC
12352005
Target
Bacterial
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-immunoregulation
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/avx-13616.html
Solubility
10 mM in DMSO
Smiles
O=C(N[C@H](CCCCN)C(N[C@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(OCCC(C)C)=O)=O)=O)COC1=[C@@]([C@@]2=C(OCCC(C)C)C=CC3=C2C=CC=C3)C(C=CC=C4)=C4C=C1.Cl.Cl
Molecular Formula
C50H73Cl2N7O7
Molecular Weight
955.06
References & Citations
[1]Avexa Presents Data from Apricitabine and Antibacterial Programs at two International Conferences
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

Popular Products